Choosing the Right Cell Line for Acute Myeloid Leukemia (AML) Research.

导出 OA

翻译打印收藏纠错

作者： Rafał,Skopek ^[1] ; Małgorzata,Palusińska ^[1] ; Katarzyna,Kaczor-Keller ^[1] ; Rafał,Pingwara ^[2] ; Anna,Papierniak-Wyglądała ^[3] ; Tino,Schenk ^[4] ; Sławomir,Lewicki ^[5] ; Artur,Zelent ^[6] ; Łukasz,Szymański ^[7]

作者单位： Department of Molecular Biology, Institute of Genetics and Animal Biotechnology, Polish Academy of Sciences, Postępu 36A, 05-552 Magdalenka, Poland. ^[1] Department of Physiological Sciences, Institute of Veterinary Medicine, Warsaw University of Life Sciences-SGGW, 02-787 Warsaw, Poland. ^[2] Polbionica Sp. z.o.o., Aleja Prymasa Tysiąclecia 79A, 01-242 Warsaw, Poland. ^[3] Department of Hematology and Medical Oncology, Clinic of Internal Medicine II, Jena University Hospital, 07747 Jena, Germany. ^[4] Institute of Molecular Cell Biology, Center for Molecular Biomedicine Jena (CMB), Jena University Hospital, 07747 Jena, Germany. ^[5] Faculty of Medical Sciences and Health Sciences, Kazimierz Pulaski University of Technology and Humanities, 26-600 Radom, Poland. ^[6] Institute of Outcomes Research, Maria Sklodowska-Curie Medical Academy, 00-001 Warsaw, Poland. ^[7]

关键词 AML cell lines AML subtypes CD markers FAB WHO genetic rearrangements

主题词人类(Humans);白血病, 髓样, 急性(Leukemia, Myeloid, Acute);突变(Mutation);核型分析(Karyotyping)

DOI 10.3390/ijms24065377

PMID 36982453

发布时间 2023-09-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交